Sierra Oncology shared positive topline results from the company’s study on the effectiveness of momelotinib to treat patients with myelofibrosis.
Palo Alto, Calif.-based BridgeBio Pharma reported topline data from Part A (Month 12) of the company’s Phase III ATTRibute-CM study of acoramidis for symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). The drug failed the study arm.
Texas A&M University Science Center, MD Anderson Cancer Center, and Pulmotect report that the drug PUL-042 appears to work against COVID-19 and other respiratory infections.
Cassava Sciences announced top-line results Sept. 22 from a 12-month interim analysis of the company’s Alzheimer’s drug candidate simufilam.
Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.
Biogen reported positive topline results from the company’s Phase II CONVEY trial of vixotrigine for the treatment of small fiber neuropathy (SFN).
Amneal Pharmaceuticals Inc announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations.
Eli Lilly announced the success of the global health care company’s clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis (AD).
Daiichi Sankyo and AstraZeneca reported positive topline data from their head-to-head DESTINY-Breast-03 Phase III trial for Enhertu versus trastuzumab emtansine (T-DM1) in patients with HER2 positive metastatic breast cancer.
French specialty vaccine maker Valneva shared positive topline results from ongoing trials for a potential single-shot vaccine against chikungunya.
